A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia AFlora Peyvandi, Frits R. Rosendaal, Ramabadran Varadarajan et al.|New England Journal of Medicine|2016Cited by 494
Timing and severity of inhibitor development in recombinant versus plasma‐derived factor VIII concentrates: a SIPPET analysisFlora Peyvandi, Bülent Zülfikar, Antonino Cannavò et al.|Journal of Thrombosis and Haemostasis|2017Cited by 40
Prediction of factor VIII inhibitor development in the SIPPET cohort by mutational analysis and factor VIII antigen measurementSilvia Spena, Bülent Zülfikar, Isabella Garagiola et al.|Journal of Thrombosis and Haemostasis|2018Cited by 33
Source of Factor VIII Replacement (PLASMATIC OR RECOMBINANT) and Incidence of Inhibitory Alloantibodies in Previously Untreated Patients with Severe Hemophilia a: The Multicenter Randomized Sippet StudyFlora Peyvandi, Rosendaal R. Frits, Brian M. Wicklund et al.|Blood|2015Cited by 21